The state of health economic evaluation research in Nigeria: A systematic review

PharmacoEconomics

Volumn 28, Issue 7, 2010, Pages 539-553

  Gavaza, Paul ^a   Rascati, Karen L ^a   Oladapo, Abiola O ^a   Khoza, Star ^a  

^a UNIVERSITY OF TEXAS AT AUSTIN   (United States)

Author keywords

health economics; pharmacoeconomics

Indexed keywords

ARTEMETHER PLUS BENFLUMETOL; ATROPINE; CLIOQUINOL; CYCLOPENTOLATE; CYCLOPHOSPHAMIDE; GENTAMICIN; GRAMICIDIN; METHOTREXATE; NEOMYCIN; OXYTETRACYCLINE; POLYMYXIN B; TROPICAMIDE; VACCINE; VINCRISTINE;

DRUG COST; ECONOMIC EVALUATION; HEALTH CARE COST; HEALTH ECONOMICS; HEALTH STATUS; HUMAN; MEDICAL INFORMATION; MEDICAL RESEARCH; NIGERIA; OTITIS MEDIA; PRIORITY JOURNAL; REVIEW; SYSTEMATIC REVIEW;

DATABASES, BIBLIOGRAPHIC; ECONOMICS, PHARMACEUTICAL; HEALTH CARE COSTS; HUMANS; NIGERIA; RESEARCH DESIGN;

EID: 77953710261     PISSN: 11707690     EISSN: 11792027     Source Type: Journal    
DOI: 10.2165/11536170-000000000-00000     Document Type: Review

References (71)

1. Wammanda RD, Ejembi CL, Lorliam T. Drug treatment costs: projected impact of using the intergrated management of childhood illnesses. Trop Doct 2003; 33: 86-88
2. Hargreaves S. Time to right the wrongs: improving basic health care in Nigeria. Lancet 2002; 359 (9322): 2030-2035
3. Wouters A. The cost and efficiency of public and private health care facilities in Ogun state, Nigeria. Health Econ 1993; 2 (1): 31-42
4. Ojanuga DN. Construction of Mujedawa dispensary in Kaduna state, Nigeria through self-help. World Health Forum 1985; 6: 108-109
5. Gustafsson-Wright E, van derGaag J.An analysis ofNigeria's health sector by state: recommendations for the expansion of the Hygeia Community Health Plan. Amsterdam: Amsterdam Institute for International Development (AIID), 2008 [online]. Available from URL: http://www.aiid.org/ docs/ NigeriaHealthSectorReport%202008.pdf [Accessed 2010 Mar 20]
6. Waka UA. ISPOR International Fellowship Report: development of pharmacoeconomics and outcomes research in Nigeria. ISPOR Connections 2009 May/June; 15 (3): 19-20
7. Famuyiwa OO, Edozien EM, Ukoli CO. Social, cultural and economic factors in the management of diabetes mellitus in Nigeria. Afr J MedMed Sci 1985 Sep-Dec; 14 (3-4): 145-154
8. Johnson D. Nigeria: a paper produced by DFID's Health Systems Resource Centre for the UK Department for International Development. London: DFID Health Systems Resource Centre: Country Health Briefing Paper, 2000 [online]. Available from URL: http://www.dfidhealthrc. org/publications/Country-health/Nigeria.pdf [Accessed 2010 Mar 20]
9. Lambo E. An optimization-simulation model of a rural health center in Nigeria. Interfaces 1983; 13: 29-35
10. Drummond MF, Sculpher MJ, Torrance GW, et al. Methods for the economic evaluation of health care programmes. 3rd ed. Oxford: Oxford University Press, 2005
11. Wyatt J. Use and sources of medical knowledge. Lancet 1991; 338: 1368-1373
12. Walker D, Fox-Rushby JA. Economic evaluation of communicable disease interventions in developing countries: a critical review of the published literature. Health Econ 2000; 9 (8): 681-698
13. Lee KS, Brouwer WB, Lee SI, et al. Introducing economic evaluation as a policy tool in Korea: will decision makers get quality information? A critical review of published Korean economic evaluations. Pharmacoeconomics 2005; 23 (7): 709-721
14. Gavaza P, Rascati KL, Lawson K, et al. The state of health economics and pharmacoeconomics research in Zimbabwe. Curr Therap Res 2008; 69 (3): 268-285
15. Sullivan SD, Lyles A, Luce BR, et al. AMCP guidance for submission of clinical and economic evaluation data to support formulary listing in US health plans and pharmacy benefits management organizations. J Manag Care Pharm 2001; 7 (4): 272-282
16. Zarnke K, Levine M, O'Brien B. Cost-benefit analysis in the health care literature: don't judge a study by its label. J Clin Epidemiol 1997; 50 (7): 817-822
17. Offman J, Sullivan S, Neumann P, et al. Examining the value and quality of health economic analyses: implications of utilizing the QHES. J Manag Care Pharm 2003; 9 (1): 53-61
18. Vogel RJ. Health care cost-recovery simulations from parametric estimates: methodology and results for Ogun State, Nigeria. Int J Health Plann Manage 1994; 9 (2): 183-198
19. Onwujekwe O, Chima R, Okonkwo P. Economic burden of malaria illness on households versus that of all other illness episodes: a study in five malaria holo-endemic Nigerian communities. Health Policy 2000; 54 (2): 143-159
20. Fatiregun AA, Osungbade KO, Olumide AE. Cost-effectiveness of screening methods for urinary schistosomiasis in a school-based control programme in Ibadan, Nigeria. Health Policy 2009; 89 (1): 72-77
21. Gureje O, Chisholm D, Kola L, et al. Cost-effectiveness of an essential mental health intervention package in Nigeria. World Psychiatry 2007; 6 (1): 42-48
22. Monath TP,Nasidi A. Should yellowfever vaccine be included in the expanded program of immunization in Africa? A cost-effectiveness analysis for Nigeria. Am J Trop Med Hyg 1993; 48 (2): 274-299
23. Adegbehingbe OO, Akinyoola AL, Ariyibi AL, et al. Direct integration of government funding and family support for musculoskeletal tumor care in a resource-constrained country. Oncology 2009; 76 (6): 398-404
24. Tongo OO, Orimadegun AE, Ajayi SO, et al. The economic burden of preterm/very low birth weight care in Nigeria. J Trop Pediatr 2009; 55 (4): 262-264
25. Olusanya BO, Emokpae A, Renner JK, et al. Costs and performance of early hearing detection programmes in Lagos, Nigeria. Trans R Soc Trop Med Hyg 2009; 103 (2): 179-186
26. Chisholm D, Gureje O, Saldivia S, et al. Schizophrenia treatment in the developing world: an interregional and multinational cost-effectiveness analysis. Bull World Health Organ 2008; 86 (7): 542-551
27. Mahal A, Canning D, Odumosu K, et al. Assessing the economic impact of HIV/AIDS on Nigerian households: a propensity score matching approach. AIDS 2008; 22 Suppl. 1: S95-101
28. Goldie SJ, O'Shea M, Campos NG, et al. Health and economic outcomes of HPV 16,18 vaccination in 72 GAVIeligible countries. Vaccine 2008; 26 (32): 4080-4093
29. Henshaw SK, Adewole I, Singh S, et al. Severity and cost of unsafe abortion complications treated in Nigerian hospitals. Int Fam Plan Perspect 2008; 34 (1): 40-50
30. Onwujekwe O, Uzochukwu B, Eze S, et al. Improving equity in malaria treatment: relationship of socio-economic status with health seeking as well as with perceptions of ease of using the services of different providers for the treatment of malaria in Nigeria. Malar J 2008; 7 (5): 1-10
31. Fatiregun AA, Yisa IO, Olumide AE. Utilization and costs of medical services at military health facilities in Ibadan, Nigeria. J Med Sys 2007; 31 (6): 505-509
32. Sadoh WE, Oviawe O. The economic burden to families of HIV and HIV/tuberculosis coinfection in a subsidized HIV treatment program. J Natl Med Assoc 2007; 99 (6): 627-631
33. Jimoh A, Sofola O, Petu A, et al. Quantifying the economic burden of malaria in Nigeria using the willingness to pay approach. Cost Eff Res Alloc 2007; 5: 1-6
34. Ebri A, Kuper H, Wedner S. Cost-effectiveness of cycloplegic agents: results of a randomized controlled trial in Nigerian children. Invest Ophthalmol Vis Sci 2007; 48 (3): 1025-1031
35. Okogun GRA, Amadi AN. Epidemiology, therapeutic agents and cost of management of paediatric malaria in a Nigerian tertiary hospital. J Vector Borne Dis 2005; 42 (3): 87-94
36. Amoo G, Ogunlesi AO. Financial cost of treating Nigerian in-patients with schizophrenia. Afr J MedMed Sci 2005; 34 (1): 15-23
37. Meremikwu MM, Ehiri JE, Nkanga DG, et al. Socioeconomic constraints to effective management of Burkitt's lymphoma in south-eastern Nigeria. Trop Med Int Health 2005; 10 (1): 92-98
38. Onwujekwe O, Uzochukwu B, Shu E, et al. Is combination therapy for malaria based on user-fees worthwhile and equitable to consumers? Assessment of costs and willingness to pay in Southeast Nigeria. Acta Trop 2004; 91 (2): 101-115
39. Onwujekwe O, Chima R, Shu E, et al. Community-directed treatment with ivermectin in two Nigerian communities: an analysis of first year start-up processes, costs and consequences. Health Policy 2002; 62 (1): 31-51
40. Onwujekwe O, Shu E, Onwuameze O, et al. Onchocerciasis control in Nigeria: will households be able to afford community- directed treatment with ivermectin? Acta Trop 2001; 80 (3): 277-281
41. Onwujekwe OE, Shu EN, Nwagbo D, et al. Willingness to pay for community-based ivermectin distribution: a study of three onchocerciasis-endemic communities in Nigeria. Trop Med Int Health 1998; 3 (10): 802-808
42. Chiwuzie J, Okojie O, Okolocha C, et al. Emergency loan funds to improve access to obstetric care in Ekpoma, Nigeria. The Benin PMM Team. Int J Gynaecol Obstet 1997; 59 Suppl. 2: S231-6
43. Amadasun JE. The cost effective medical treatment of suppurative otitis media in a Nigerian environment. West Afr J Med 1997; 16 (2): 85-87
44. Ogunbekun I, Adeyi O, Wouters A, et al. Costs and financing of improvements in the quality of maternal health services through the Bamako Initiative in Nigeria. Health Policy Plan 1996 Dec 1; 11 (4): 369-384
45. Konje JC, Obisesan KA, Ladipo OA. Health and economic consequences of septic induced abortion. Int J Gynecol Obstet 1992; 37 (3): 193-197
46. Ogunseitan OA. The cost of environmental lead (Pb) poisoning in Nigeria. African J Environ Sci Technol 2007; 1 (2): 27-36
47. Onwujekwe O, Chima R, Shu E, et al. Altruistic willingness to pay in community-based sales of insecticide-treated nets exists in Nigeria. Soc Sci Med 2002; 54 (4): 519-527
48. Onwujekwe O, Chima R, Shu E, et al. Hypothetical and actual willingness to pay for insecticide-treated nets in five Nigerian communities. Trop Med Int Health 2001; 6 (7): 545-553
49. Suleiman TG, Ohaeri JU, Lawal RA, et al. Financial cost of treating out-patients with schizophrenia in Nigeria. Br J Psychiatry 1997; 171: 364-368
50. Onwujekwe O, Dike N, Chukwuka C, et al. Examining catastrophic costs and benefit incidence of subsidized antiretroviral treatment (ART) programme in south-east Nigeria. Health Policy 2009; 90 (2-3): 223-229
51. Onwujekwe O, Hanson K, Fox-Rushby J. Inequalities in purchase of mosquito nets and willingness to pay for insecticide- treated nets in Nigeria: challenges for malaria control interventions. Malar J 2004; 3 (6): 1-8
52. Alhasan SU, Aji SA, Mohammed AZ, et al. Transurethral resection of the prostate in Northern Nigeria, problems and prospects. BMC Urol 2008; 8 (18): 1-6
53. Isenalumhe AE, Oviawe O. Polypharmacy: its cost burden and barrier to medical care in a drug-oriented health care system. Int J Health Serv 1988; 18 (2): 335-342
54. Makanjuola AB. A cost comparison of traditional and orthodox mental health care. Niger Postgrad Med J 2003; 10 (3): 157-161
55. Gosselin R, Maldonado A, Elder G. Comparative costeffectiveness analysis of two MSF surgical trauma centers. World J Surg 2010; 34 (3): 415-419
56. Veeken H, Ritmeijer K, Hausman B. Priority during a meningitis epidemic: vaccination or treatment? Bull World Health Organ 1998; 76 (2): 135-141
57. Onwujekwe O, Uzochukwu B, Nwobe E, et al. Socioeconomic inequalities in household expenditures to prevent and treat endemic tropical diseases in Southwest Nigeria. J Int Med Res 2004; 2: 29-39
58. Enwere OO, Salako BL, Falade CO. Prescription and cost consideration at a diabetic clinic in Ibadan,Nigeria: a report. Ann Ibadan Postgrad Med 2006; 4 (2): 35-39
59. Adeneye AK, Mafe MA, Appelt B, et al. Willingness to pay for praziquantel treatment in a hyperendemic community of Ogun State, Nigeria. Res Social Admin Pharm 2006; 2 (1): 83-95
60. Teerawattananon Y, Russell S, Mugford M. A systematic review of economic evaluation literature in Thailand: are the data good enough to be used by policy-makers? Pharmacoeconomics 2007; 25 (6): 467-479
61. Neumann PJ, Stone PW, Chapman RH, et al. The quality of reporting in published cost-utility analyses, 1976-1997. Ann Int Med 2000; 132 (12): 964-972
62. Federal Ministry of Health. The national health policy of Nigeria. Lagos: Federal Ministry of Health, 1992
63. Federal Ministry of Health. National strategic plan for roll back malaria in Nigeria 2001. Abuja: Federal Ministry of Health, 2001
64. Ejezie GC, Ezedinachi EN, Usanga EA, et al. Malaria and its treatment in rural villages of Aboh Mbaise, Imo State Nigeria. Acta Trop 1990 Oct; 48 (1): 17-24
65. Drummond MF, Iglesias CP, Cooper NJ. Systematic reviews and economic evaluations conducted for the National Institute for Health and Clinical Excellence in the United Kingdom: a game of two halves? Int J Technol Assess Health Care 2008 Spring; 24 (2): 146-150
66. Gerard K. Cost-utility in practice: a policy maker's guide to the state of the art. Health Policy 1992; 21 (3): 249-279
67. Udvarhelyi IS, Colditz GA, Rai A, et al. Cost-effectiveness and cost-benefit analyses in the medical literature: are the methods being used correctly? Ann Int Med 1992; 116 (3): 238-244
68. Adams ME, McCall NT, Gray DT, et al. Economic analysis in randomized control trials. Med Care 1992; 30 (3): 231-243
69. Freemantle N, Mason J. Publication bias in clinical trials and economic analyses. Pharmacoeconomics 1997; 12 (1): 10-16
70. Bell CM, Urbach DR, Ray JG, et al. Bias in published cost effectiveness studies: systematic review. BMJ 2006; 332 (7543): 699-701
71. Hillman AL, Eisenberg JM, Pauly MV, et al. Avoiding bias in the conduct and reporting of cost-effectiveness research sponsored by pharmaceutical companies. J Res Pharm Econ 1992; 4 (2): 3-13